Mandate

Vinge advises Orexo

March 15, 2010

Orexo AB (publ) listed on NASDAQ OMX Stockholm is carrying out a convertible bond issue in the amount of SEK 111 million directed to Novo A/S concurrently with Novo acquiring Apax and SLS Invest's shareholdings in Orexo.
 
The Vinge team advising Orexo in the transaction primarily consists of Erik Sjöman, Christian Lindhé and Dain Nevonen. 

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025